mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerabilityNiklas Gremke, Thorsten Stiewe|Nature Communications|2020Cited by 171
Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferasesJoël P. Charles, Thorsten Stiewe|Nature Communications|2014Cited by 46
Phosphorylation Control of p53 DNA-Binding Cooperativity Balances Tumorigenesis and AgingOleg Timofeev, Thorsten Stiewe|Cancer Research|2020Cited by 30
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugsNiklas Gremke, Thorsten Stiewe, Anne‐Sophie Litmeyer et al.|Signal Transduction and Targeted Therapy|2025Cited by 19
Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasisEvangelos Pavlakis, Thorsten Stiewe|Journal of Experimental & Clinical Cancer Research|2023Cited by 19